News

Viread is indicated for HIV-1 infected children between two to six years of age and for HIV-1 infected children more than six years for whom solid dosage is

Under the agreement, UMN Pharma and its subsidiary, UNIGEN, will use Catalent’s GPEx technology for producing a number of biosimilars. UMN Pharma said for product development including clinical

The collaboration will also be involved in evaluating the new therapeutics in proof-of-concept clinical trials. To implement the development, the companies will form a Therapeutic Innovation Group (TIG),

The Phentermine product lines include phentermine HCl tablets 37.5mg and phentermine HCl capsules 15mg and 30mg. The purchase orders will allow the company to obtain required amounts of

The termination of one of three Phase 3 rheumatoid arthritis registration studies of the anti-BAFF monoclonal antibody is not due to safety concerns and patients presently enrolled in

The solution also allows the research files to be automatically uploaded into the correct file, without human intervention. I-Batch eliminates the manual document sorting and uploading process by

The trial was designed to evaluate safety and also to provide proof-of-concept for the ability of the compound to inhibit excessive uterine contractility. During the study the healthy

The BZA/CE is an investigational therapy developed by Wyeth Pharmaceuticals to tackle symptoms such as vasomotor symptoms and vulvar and vaginal atrophy associated with menopause and for prevention

MM-141, the company’s sixth oncology candidate that advanced into clinical development, is developed to target P13K/AKT/mTOR pathway that is believed to play a vital role in tumor cell